eli lilly trial retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II Eli Lilly's tirzepatide showed positive
Description
To support tolerance, GLP-1 treatment is started at a low dose and titrated upward, which helps reduce gastrointestinal side effects like nausea that can affect 20% to 40% of patients when treatment begins , as noted in the earlier payer-focused clinical guidance
Individual results vary Common considerations: Similar stomach-related side effects during titration
Understanding what clinical research demonstrates-and what it doesn't-helps set realistic expectations
EMA will communicate further when appropriate
bsm-33199M), anti-Bax (cat
